z-logo
open-access-imgOpen Access
Comparison of serum testosterone levels in prostate cancer patients
Author(s) -
Seetha Venkateswaran,
David Margel,
Stanley A. Yap,
Karen Hersey,
P. Yip,
Neil Fleshner
Publication year - 2013
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.377
Subject(s) - testosterone (patch) , prostate cancer , medicine , prostate , urology , luteinizing hormone , interquartile range , endocrinology , prostatectomy , prostate specific antigen , hormone , cancer
The prostate secretes enzymes and nutrients to promote sperm motility. Recent reports suggest that the prostate may also secrete testosterone, which is believed to be a fuel for prostate tumour growth. The aim of this study was to determine if a difference in serum testosterone levels exists between men on luteinizing hormone releasing-hormone (LHRH) agonists who have undergone radical prostatectomy, radiation or hormone therapy as primary prostate cancer treatment.Methods: Serum testosterone levels were evaluated in 165 consecutive prostate cancer patients using LHRH analogues for >3 months. We excluded patients receiving either radiation or chemotherapy at time of time of testosterone measurement. Patients were classified based on primary treatment: (1) radical prostatectomy; (2) radiation; or (3) primary hormone therapy. We used one-way ANOVA to compare testosterone levels. Pearson correlation was used to correlate testosterone with prostate-specific antigen (PSA) and time on LHRH agonists. Multivariable linear regression was used to predict serum testosterone levels.Results: The median (interquartile range) serum testosterone levels were 1.4 (1-1.9), 1.3 (1-1.625) and 1.25 (0.9-1.525) nmol/L for radical prostatectomy, radiation and primary hormone therapy groups, respectively. There was no statistically significant difference in testosterone levels between the groups (p = 0.3). No correlation was found between testosterone and PSA levels or time on LHRH (r = 0.02 and r = 0.01), respectively. Multivariable linear regression showed that none of the clinical variables were predictors ofserum testosterone levels.Conclusion: Our study suggests that primary treatment does notaffect serum testosterone levels among men using LHRH analogues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here